Artificial Bone Material Market Size and Industry Share 2021: Business Growth Insights, Global Industry Overview, Manufacturing Cost, Competitive Analysis,Opportunities and Challenges, and Research Forecast to 2027
Apr 16, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Artificial Bone Material Market”...
The Express Wire · 16h ago
SeaSpine raises $88M via equity offering
SeaSpine Holdings (SPNE) has priced its public offering of 4.5M common shares at $19.50/share, for expected gross proceeds of ~$87.8M.Underwriters' over-allotment is an additional 675K shares. Net proceeds will be
Seekingalpha · 21h ago
SeaSpine Holdings Prices Offering at $19.50 Per Share
MT Newswires · 22h ago
BRIEF-Seaspine Prices Public Offering Of Common Stock · 23h ago
PGNY, XELB, SPNE and SYBX among after-hours movers
Gainers: [[PGNY]] +7.9%. [[XELB]] +7.0%. [[IDYA]] +6.9%. [[LSCC]] +6.6%. [[DKNG]] +6.0%.Losers: [[SPNE]] -3.8%. [[DBVT]] -3.4%. [[SYBX]] -3.0%. [[SESN]] -2.6%. [[DSEY]] -2.5%.
Seekingalpha · 1d ago
SeaSpine under pressure on stock offering
SeaSpine (SPNE) trades 9.2% down after hours on commencing an underwritten public offering of shares; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms not
Seekingalpha · 1d ago
BRIEF-SeaSpine Commences Public Offering Of Common Stock · 1d ago
SeaSpine Commences Public Offering of Common Stock
CARLSBAD, Apr 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- CARLSBAD, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE)...
GlobeNewswire · 1d ago
SeaSpine Holdings Starts Common Stock Offering
MT Newswires · 1d ago
Global Orthobiologics Market 2020 - Industry Analysis and In-Depth Research Growth with Major key players in 2026
Apr 14, 2021 (CDN Newswire via Comtex) -- A superior and comprehensive market research report entitled Global Orthobiologics Market Growth 2020-2026 contains...
CDN Newswire · 2d ago
Investors Who Bought SeaSpine Holdings (NASDAQ:SPNE) Shares A Year Ago Are Now Up 143%
Unfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really...
Simply Wall St. · 4d ago
Orthobiologics Market to Register Stunning Growth by 2031 | Players: Medtronic plc and NuVasive Inc.
Apr 12, 2021 (WiredRelease via Comtex) -- adopted a multidisciplinary detain during the pandemic-era to focus on the revolutionary trends, growth... · 4d ago
DJ SeaSpine Holdings on Track for Highest Close Since June 2015 -- Data Talk
Dow Jones · 04/08 17:16
Lilly woes provide buying opportunity, Danaher a buy with likely earnings beat, and more in today's analyst action
Lilly's recent setback provide buying opportunityAlthough Eli Lilly's (LLY) share price has been hit since reporting after the bell on Tuesday that the FDA is extending the review of an
Seekingalpha · 04/08 13:26
DJ SeaSpine Holdings Raised to Overweight From Equal-Weight by Wells Fargo
Dow Jones · 04/08 10:31
DJ SeaSpine Holdings Price Target Announced at $24.00/Share by Wells Fargo
Dow Jones · 04/08 10:31
Wells Fargo Upgrades SeaSpine Holdings to Overweight, Announces $24 Price Target
Wells Fargo analyst Shagun Singh upgrades SeaSpine Holdings (NASDAQ:SPNE) from Equal-Weight to Overweight and announces $24 price target.
Benzinga · 04/08 10:22
SeaSpine (SPNE) Surges 13.2%: Is This an Indication of Further Gains? · 04/07 15:11
Brooklyn ImmunoTherapeutics, Greenwich LifeSciences leads healthcare gainers; Scholar Rock, Chembio Diagnostics among major losers
Gainers: Brooklyn ImmunoTherapeutics (BTX) +45%, Greenwich LifeSciences (GLSI) +16%, PAVmed (PAVM) +15%, SeaSpine Holdings (SPNE) +14%, Cara Therapeutics (CARA) +14%.Losers: Scholar Rock (SRRK) -14%, Chembio Diagnostics (CEMI) -13%, Harmony Biosciences (HR...
Seekingalpha · 04/06 15:00
Webull provides a variety of real-time SPNE stock news. You can receive the latest news about SeaSpine Hldg through multiple platforms. This information may help you make smarter investment decisions.
About SPNE
SeaSpine Holdings Corporation is a medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company offers a portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. Its spinal implants portfolio consists of a line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Orthobiologics products are used in orthopedic and dental procedures and consist of a range of bone graft substitutes to address the key elements of bone regeneration -osteoinduction, osteoconduction and osteogenesis. Spinal implant portfolio consists of a line of products for spinal decompression alignment and stabilization.